ORIGINAL RESEARCH article Front. Neurol., 11 March 2020 Sec. Applied Neuroimaging Volume 11 - 2020 | https://doi.org/10.3389/fneur.2020.00179 Assessment and Rating of Motor Cerebellar Ataxias With the Kinect v2 Depth Sensor: Extending Our Appraisal
Neurology meeting in 北多摩 (2021/9/17) 初回入院後の経過からパーキンソン病精神症状を考える
7th Congress of AsCNP (2021/10/22-23) 5-HT1A agonist improves psychiatric hyperlocomotion in a mouse model of Parkinson’s disease caused by dopamine deficiency.
60th Annual Meeting of ACNP (2021/12/5-8) 5HT1A agonist is involved in psychiatric symptoms in a mouse model of Parkinson's disease, and suppressing activity of the median raphe nucleus may be the key.
The Lancet Summit (2021/12/14-16) The 5HT-1A receptor targeted drugs may help to prevent the appearance of psychosis with Parkinson’s disease.
Ochiai Y, Fujita M, Hagino Y, Kobayashi K, Okiyama R, Takahashi K, Ikeda K
The therapeutic effects of 5-HT1A receptor agonist on the psychomotor hyperactivity in dopamine-deficient mice.
33rd CINP World Congress of Neuropsychopharmacology, Virtual & Taipei, Taiwan